Published in Br J Psychiatry on August 01, 2005
Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry (2013) 0.98
Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat (2008) 0.98
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat (2007) 0.88
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat (2010) 0.81
Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa. Ann Gen Psychiatry (2013) 0.80
Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients. Psychopharmacology (Berl) (2008) 0.77
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat (2016) 0.75
Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. Schizophr Bull (2015) 0.75
[Pharmacotherapy for schizophrenia]. Nervenarzt (2006) 0.75
Advancing paternal age and autism. Arch Gen Psychiatry (2006) 3.58
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry (2005) 2.52
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry (2003) 2.24
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry (2004) 1.82
Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull (2008) 1.81
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol (2009) 1.76
A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry (2002) 1.72
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry (2004) 1.70
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res (2007) 1.68
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry (2003) 1.66
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res (2009) 1.62
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry (2009) 1.61
Osteoporosis in patients with schizophrenia. Am J Psychiatry (2005) 1.58
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry (2007) 1.58
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry (2005) 1.55
The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res (2003) 1.51
A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. Addiction (2008) 1.49
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2007) 1.46
Paternal age and intelligence: implications for age-related genomic changes in male germ cells. Psychiatr Genet (2005) 1.42
Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry (2004) 1.42
School-based obesity prevention programs: a meta-analysis of randomized controlled trials. Obesity (Silver Spring) (2013) 1.41
Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2009) 1.40
Reversal of cocaine-conditioned place preference and mesocorticolimbic Zif268 expression by social interaction in rats. Addict Biol (2011) 1.36
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry (2005) 1.34
Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging (2006) 1.33
The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry (2008) 1.32
Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res (2003) 1.26
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther (2008) 1.25
Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry (2004) 1.25
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology (2010) 1.24
Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol (2004) 1.18
Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol (2006) 1.17
Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res (2004) 1.15
Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord (2005) 1.15
Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage (2010) 1.15
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat (2011) 1.13
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry (2004) 1.13
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol (2004) 1.10
Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res (2007) 1.09
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res (2006) 1.09
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol (2005) 1.08
Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res (2005) 1.08
The relationship of premorbid functioning to illness course in schizophrenia and psychotic mood disorders during two years following first hospitalization. J Nerv Ment Dis (2006) 1.07
Socioeconomic status at birth is associated with risk of schizophrenia: population-based multilevel study. Schizophr Bull (2007) 1.06
Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs (2012) 1.06
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol (2005) 1.06
Correlates of insight in first episode psychosis. Schizophr Res (2004) 1.06
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol (2008) 1.05
Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry (2006) 1.05
Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry (2005) 1.05
Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry (2010) 1.04
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry (2003) 1.04
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol (2008) 1.04
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res (2006) 1.04
Various bilateral olfactory deficits in male patients with schizophrenia. Schizophr Bull (2005) 1.04
Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. Eur Psychiatry (2008) 1.03
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry (2004) 1.03
Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist (2010) 1.02
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Never too old for eating disorders or body dissatisfaction: a community study of elderly women. Int J Eat Disord (2006) 1.01
Reduced olfactory sensitivity, discrimination, and identification in patients with alcohol dependence. Alcohol Clin Exp Res (2003) 1.01
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol (2004) 1.01
Brain activation patterns during a selective attention test-a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Res (2003) 1.01
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol (2005) 1.01
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol (2008) 1.01
Hopelessness as a predictor of attempted suicide among first admission patients with psychosis: a 10-year cohort study. Suicide Life Threat Behav (2012) 1.00
Social and cognitive functioning, urbanicity and risk for schizophrenia. Br J Psychiatry (2007) 0.99
Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer (2008) 0.99
Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord (2005) 0.98
Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. ScientificWorldJournal (2005) 0.98
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls. Eur J Haematol (2005) 0.97
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry (2008) 0.96
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J Clin Psychopharmacol (2007) 0.95
Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res (2011) 0.95
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol (2009) 0.95
No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res (2004) 0.95
Quality of life trajectory in patients with advanced cancer during the last year of life. J Palliat Med (2011) 0.94
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res (2008) 0.94
Correlates, change and 'state or trait' properties of insight in schizophrenia. Schizophr Res (2010) 0.93
The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients. Schizophr Res (2004) 0.93
The EORTC emotional functioning computerized adaptive test: phases I-III of a cross-cultural item bank development. Psychooncology (2013) 0.92
Impairment in emotion recognition abilities in patients with mild cognitive impairment, early and moderate Alzheimer disease compared with healthy comparison subjects. Am J Geriatr Psychiatry (2008) 0.92
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol (2005) 0.92
Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry (2003) 0.92
Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients. Health Qual Life Outcomes (2011) 0.91
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res (2005) 0.91
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry (2002) 0.91
Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol (2005) 0.91
Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients. Psychiatry Res (2005) 0.91
Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes (2009) 0.91
Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry (2003) 0.90
The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology (2007) 0.89
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry (2004) 0.89
Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manage (2012) 0.88
Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin. J Psychiatr Res (2006) 0.88
Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging (2005) 0.88
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol (2006) 0.87